Opioid induced hyperalgesia: Clinical implications for the pain practitioner

Pain Physician

Volumn 12, Issue 3, 2009, Pages 679-684

  Silverman, Sanford M ^a  

^a Comprehensive Pain Medicine ^*  (United States)

Author keywords

Buprenorphine and hyperalgesia; Complications of opioid therapy; Descending facilitation and hyperalgesia; Hyperalgesia; NMDA receptor antagonists; NMDA receptor induced hyperalgesia; Office based detoxification; Opioid detoxification; Opioid hyperalgesia; Spinal dynorphin induced hyperalgesia; Tolerance

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CALCITONIN GENE RELATED PEPTIDE; CHOLECYSTOKININ; CLONIDINE; DYNORPHIN; DYNORPHIN DERIVATIVE; GLUTAMATE TRANSPORTER; METHADONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPEPTIDE Y; OPIATE; VASOACTIVE INTESTINAL POLYPEPTIDE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

APOPTOSIS; CHRONIC PAIN; DOSE RESPONSE; EXCITATORY JUNCTION POTENTIAL; FACILITATION; HUMAN; HYPERALGESIA; LOW DRUG DOSE; NEUROBIOLOGY; NEUROPATHIC PAIN; NEUROTOXICITY; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PAIN THRESHOLD; PHYSICIAN; REVIEW; SENSITIZATION; THALAMUS VENTRAL NUCLEUS; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED DISORDER; DRUG DETOXIFICATION; DRUG EFFECT; DRUG TOLERANCE; METABOLISM; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANALGESICS, OPIOID; BUPRENORPHINE; CENTRAL NERVOUS SYSTEM; DRUG TOLERANCE; DYNORPHINS; HUMANS; HYPERALGESIA; METABOLIC DETOXICATION, DRUG; NARCOTIC ANTAGONISTS; PAIN; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 69849096806     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. American Society of Addiction Medicine (ASAM). Definitions Related to the Use of Opioids for the Treatment of Pain: A Consensus Document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. American Academy of Pain Medicine, Glenview, IL, 2001.
2. Albutt C. On the abuse of hypodermic injections of morphia. Practitioner 1870; 5:327-331.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). American Psychiatric Press. Washington, DC, 1994.
4. American Society of Addiction, Principles of Addiction Medicine, 3rd edition, Medicine, 2003, pp 3-16.
5. Yaksh Tl, Malmberg AB. Central pharmacology of nociceptive transmission. In Wall P, Melzack (eds): Textbook of Pain, 3rd ed, 1994; pp. 165-200.
6. Mao J. Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain 2002; 100:213-217. (Pubitemid 35449233)
7. Mao J, Price D, Mayer D. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain 1995; 62:259-274.
8. Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, Simonnet G. Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology 2000; 92:465-472. (Pubitemid 30078345)
9. Celerier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: A sensitization process. J Neurosci 2001; 21:4074-4080. (Pubitemid 32466499)
10. Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P, Fletcher D, Chauvin M. Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000; 93:409-417. (Pubitemid 30620314)
11. Baron, MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high dose opioids. J Opioid Manag 2006; 2:277-282.
12. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug and Alcohol Dependence 2001; 63:139-146. (Pubitemid 32488928)
13. Angst MS, Clark JD. Opioid-induced Hyperalgesia: A qualitative systematic review. Anesthesiology 2006; 104:570-587.
14. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991; 251:85-87. (Pubitemid 21916858)
15. Marek P, Ben Eliyahu S, Gold M, Liebeskind JC. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Research 1991; 547:77-81.
16. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994; 14:2301-2312. (Pubitemid 24108135)
17. Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002; 22:8312-8323. (Pubitemid 35379137)
18. Narita M, Mizoguchi H, Nagase H, Suzuki T, Tseng LF. Involvement of spinal protein kinase C gamma in the attenuation of opioid-mu-receptor mediated G-protein activity after chronic intrathecal administration of [D-Ala2,N-Mephe4, Gly-Ol5] enkephalin. J Neurosci 2001; 21:3715-3720. (Pubitemid 32466462)
19. Zeitz KP, Malmberg AB, Gilbert H, Bas baum AI. Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice. Pain 2002; 94:245-253. (Pubitemid 33145394)
20. Mao J. NMDA and opioid receptors: Their interactions in anti-nociception, tolerance and neuroplasticity. Brain Res Rev 1999; 30:289-304. (Pubitemid 29531489)
21. Mao J, Price DD, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: Implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995; 61:353-364.
22. Mao J, Sung B, Ru-Rong J, Grewo L. Neuronal apoptosis associated with morphine tolerance: Evidence for an opioid-induced neurotoxic mechanism. J Neurosci 2002; 22:7650-7661. (Pubitemid 35386364)
23. Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan Jr. TP, Lai J, Porreca F. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release form primary afferent fibers. J Neurosci 2002; 22:6747-6755. (Pubitemid 35386431)
24. Barbaro NM, Heinricher MM, Fields HL. Putative pain modulating neurons in the rostral ventral medulla: Reflex-related activity predicts effects of morphine. Brain Research 1986; 366:203-210.
25. Heinricher MM, Morgan MM, Fields HL. Direct and indirect actions of morphine on medullary neurons that modulate nociception. Neuroscience 1992; 48:533-543.
26. Morgan MM, Heinricher MM, Fields HL. Circuitry linking opioid-sensitive nociceptive modulatory systems in periaqueductal gray and spinal cord with rostral ventromedial medulla. Neuroscience 1992; 47:863-871.
27. Davis A, Inturrisi C. d-Methadone blocks morphine tolerance and N-Methyl-D-aspartate-induced. The Journal of Pharmacology and Experimental Therapeutics 1999; 289:1048-1053.
28. Vorobeychik Y, Chen L, Bush MC, Mao J. Improved opioid analgesic effect following opioid dose reduction. Pain Med 2008; 9:724-727.
29. Johnson RE, Fudala PJ, Payne R. Buprenorphine: Considerations for pain management. J Pain Symptom Manag 2005; 29:297-326.
30. Koppert W, Ihmsen H, Korber N, Wehrfritz A, Sittl R, Schmelz M. Different profiles of buprenorphine induced analgesia and antihyperalgesia in a human pain model. Pain 2005; 118:15-22. (Pubitemid 41566581)
31. Helm S, Trescot A, Colson J, Sehgal N, Silverman S. Opioid antagonists, partial agonists, and agonists/antagonists: The role of office-based detoxification. Pain Physician 2008; 11:225-235. (Pubitemid 351546233)
32. Dole VP, Narcotic addiction, physical dependence and relapse. N Engl J Med 1972; 286:988-992.
33. Kosten TR, Current pharmacotherapies for opioid dependence. Psychopharmacology Bulletin 1990; 26:69-74.
34. Heit HA, Covington E, Good PA. Dear DEA. Pain Med 2004; 5:303-308.
35. Davis MP, Shaiova LA, Angst M. When opioids cause pain. Journal of Clinical Oncology 2007; 25:4497-4498.
36. Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain Cochrane Database Systematic Review 2003; CD003351.
37. McQueen AL, Baroletti SA. Adjuvant ketamine analgesia for the management of cancer pain. Annals Pharmacotherapy 2002; 36:1614-1619.
38. Mercadante S, Villari P, Ferrera P. Burst ketamine to reverse opioid tolerance in cancer pain. Journal of Pain and Symptom Management 2003; 25:302-305. (Pubitemid 36411784)
39. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997; 73:123-139.
40. Sites BD, Beach M, Biggs R, Rohan C, Wiley C, Rassias A. Gregory J, Fanciullo G. Intrathecal clonidine added to a bupivacaine-morphine spinal anesthetic improves postoperative analgesia for total knee arthroplasty. Anesth Analg 2003; 96:1083-1088. (Pubitemid 36359048)
41. Tumber PS, Fitzgibbon DR. The control of severe cancer pain by continuous intrathecal infusion and patient controlled intrathecal analgesia with morphine, bupivacaine and clonidine. Pain 1998; 78:217-220.
42. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Ossipov MH, Lai J, Porreca F, Malan TP Jr. Production of paradoxical sensory hypersensitivity by alpha2-adrenoreceptor agonist. Anesthesiology 2004; 100:1538-1544. (Pubitemid 38679326)
43. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, Patel S, Manchikanti L. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician 2008; 11:S12-S16. (Pubitemid 351682078)